zolpidem has been researched along with Idiopathic Parkinson Disease in 12 studies
Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.
zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zolpidem use might unmask preclinical Parkinson's disease, especially in patients with depression." | 3.81 | Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study. ( Huang, HC; Kao, CH; Lin, KH; Lu, MK; Muo, CH; Sung, FC; Tsai, CH, 2015) |
| "To illustrate the beneficial effect of zolpidem on the neuropsychiatric and motor symptoms in a patient with Parkinson disease (PD) after bilateral subthalamic nucleus deep brain stimulation." | 3.78 | Zolpidem improves neuropsychiatric symptoms and motor dysfunction in a patient with Parkinson's disease after deep brain stimulation. ( Chiou, SM; Hsu, YT; Huang, HY; Kao, CH; Tsai, CH; Tsai, MC; Wu, YC, 2012) |
| "Zolpidem is an imidazopyridine agonist with a high affinity on the benzodiazepine site of GABA(A) receptors containing alpha 1 subunit." | 1.34 | Zolpidem modulates GABA(A) receptor function in subthalamic nucleus. ( Chen, L; Fung, KS; Xie, JX; Yung, WH, 2007) |
| "Patients with Parkinson's disease have been known to have sleep disturbances of various types." | 1.33 | [A hypnotic drug for sleep disturbances in patients with Parkinson's disease]. ( Abe, K; Hikita, T; Sakoda, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, YW | 1 |
| Hsieh, TF | 1 |
| Yu, CH | 1 |
| Huang, YS | 1 |
| Lee, CC | 1 |
| Tsai, TH | 1 |
| Hall, SD | 1 |
| Prokic, EJ | 1 |
| McAllister, CJ | 1 |
| Ronnqvist, KC | 1 |
| Williams, AC | 1 |
| Yamawaki, N | 1 |
| Witton, C | 1 |
| Woodhall, GL | 1 |
| Stanford, IM | 1 |
| Huang, HC | 1 |
| Tsai, CH | 2 |
| Muo, CH | 1 |
| Lin, KH | 1 |
| Lu, MK | 1 |
| Sung, FC | 1 |
| Kao, CH | 2 |
| Kojović, M | 1 |
| Gregorič Kramberger, M | 1 |
| Huang, HY | 1 |
| Hsu, YT | 1 |
| Wu, YC | 1 |
| Chiou, SM | 1 |
| Tsai, MC | 1 |
| Abe, K | 1 |
| Hikita, T | 1 |
| Sakoda, S | 1 |
| Chen, L | 1 |
| Xie, JX | 1 |
| Fung, KS | 1 |
| Yung, WH | 1 |
| Chen, YY | 1 |
| Sy, HN | 1 |
| Wu, SL | 1 |
| Daniele, A | 1 |
| Albanese, A | 1 |
| Gainotti, G | 1 |
| Gregori, B | 1 |
| Bartolomeo, P | 1 |
| Lavoisy, J | 1 |
| Marsac, J | 1 |
| Růzicka, E | 1 |
| Roth, J | 1 |
| Jech, R | 1 |
| Busek, P | 1 |
| Evidente, VG | 1 |
1 trial available for zolpidem and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Zolpidem in Parkinson's disease.
Topics: Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Female; Globus Pallidus; Humans; Hypn | 1997 |
11 other studies available for zolpidem and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Zolpidem and the risk of Parkinson's disease: a nationwide population-based study.
Topics: Adult; Analysis of Variance; Cohort Studies; Community Health Planning; Female; Humans; Hypnotics an | 2014 |
GABA-mediated changes in inter-hemispheric beta frequency activity in early-stage Parkinson's disease.
Topics: Aged; Beta Rhythm; Electroencephalography Phase Synchronization; Female; GABA-A Receptor Agonists; H | 2014 |
Risk of Parkinson's disease following zolpidem use: a retrospective, population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzodiazepines; Comorbidity; Depression; Female; Humans | 2015 |
Zolpidem withdrawal status dystonicus in the patient with advanced Parkinson's disease.
Topics: Dystonia; GABA-A Receptor Agonists; Humans; Male; Middle Aged; Parkinson Disease; Pyridines; Severit | 2015 |
Zolpidem improves neuropsychiatric symptoms and motor dysfunction in a patient with Parkinson's disease after deep brain stimulation.
Topics: Confusion; Deep Brain Stimulation; Female; Fluorodeoxyglucose F18; Humans; Hypnotics and Sedatives; | 2012 |
[A hypnotic drug for sleep disturbances in patients with Parkinson's disease].
Topics: Adult; Aged; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Parkinson Disease; Pyridine | 2005 |
Zolpidem modulates GABA(A) receptor function in subthalamic nucleus.
Topics: Animals; Flumazenil; GABA Agonists; GABA Modulators; GABA-A Receptor Agonists; GABA-A Receptor Antag | 2007 |
Zolpidem improves akinesia, dystonia and dyskinesia in advanced Parkinson's disease.
Topics: Dyskinesias; Dystonia; Humans; Hypnotics and Sedatives; Male; Middle Aged; Parkinson Disease; Pyridi | 2008 |
Zolpidem in Parkinson's disease.
Topics: Antiparkinson Agents; Humans; Hypnotics and Sedatives; Parkinson Disease; Pyridines; Zolpidem | 1997 |
Subhypnotic doses of zolpidem oppose dopaminergic-induced dyskinesia in Parkinson's disease.
Topics: Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; GABA Agonists; | 2000 |
Zolpidem improves dystonia in "Lubag" or X-linked dystonia-parkinsonism syndrome.
Topics: Adult; Dystonic Disorders; Genetic Linkage; Humans; Hypnotics and Sedatives; Male; Parkinson Disease | 2002 |